CN104524491A - 一种治疗慢性心衰的中药制剂及其制备方法 - Google Patents
一种治疗慢性心衰的中药制剂及其制备方法 Download PDFInfo
- Publication number
- CN104524491A CN104524491A CN201410758521.3A CN201410758521A CN104524491A CN 104524491 A CN104524491 A CN 104524491A CN 201410758521 A CN201410758521 A CN 201410758521A CN 104524491 A CN104524491 A CN 104524491A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- traditional chinese
- heart failure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 43
- 206010007558 Cardiac failure chronic Diseases 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 238000009835 boiling Methods 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 241000628997 Flos Species 0.000 claims description 9
- 239000009636 Huang Qi Substances 0.000 claims description 9
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 9
- 241000180649 Panax notoginseng Species 0.000 claims description 9
- 241000237636 Pheretima Species 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 6
- 239000002893 slag Substances 0.000 claims description 4
- 238000007654 immersion Methods 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 25
- 239000008280 blood Substances 0.000 abstract description 25
- 230000017531 blood circulation Effects 0.000 abstract description 10
- 230000001737 promoting effect Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 208000004880 Polyuria Diseases 0.000 abstract description 4
- 230000035619 diuresis Effects 0.000 abstract description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 3
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 208000026435 phlegm Diseases 0.000 abstract description 3
- 241000207925 Leonurus Species 0.000 abstract description 2
- 230000033228 biological regulation Effects 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 3
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 241001061264 Astragalus Species 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 abstract 1
- 241000096284 Gynochthodes officinalis Species 0.000 abstract 1
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 235000002789 Panax ginseng Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract 1
- 244000273928 Zingiber officinale Species 0.000 abstract 1
- 235000006886 Zingiber officinale Nutrition 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 235000017803 cinnamon Nutrition 0.000 abstract 1
- 241001233061 earthworms Species 0.000 abstract 1
- 235000008397 ginger Nutrition 0.000 abstract 1
- 244000237330 gutta percha tree Species 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 description 35
- 208000002193 Pain Diseases 0.000 description 18
- 210000004185 liver Anatomy 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 235000009508 confectionery Nutrition 0.000 description 11
- 108091006146 Channels Proteins 0.000 description 10
- 230000007812 deficiency Effects 0.000 description 10
- 210000003734 kidney Anatomy 0.000 description 10
- 201000000736 Amenorrhea Diseases 0.000 description 7
- 206010001928 Amenorrhoea Diseases 0.000 description 7
- 231100000540 amenorrhea Toxicity 0.000 description 7
- 230000004217 heart function Effects 0.000 description 7
- 208000006820 Arthralgia Diseases 0.000 description 6
- 206010013935 Dysmenorrhoea Diseases 0.000 description 6
- 206010027514 Metrorrhagia Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 206010007247 Carbuncle Diseases 0.000 description 5
- 208000005171 Dysmenorrhea Diseases 0.000 description 5
- 208000000059 Dyspnea Diseases 0.000 description 5
- 206010013975 Dyspnoeas Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 208000029078 coronary artery disease Diseases 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 208000019255 Menstrual disease Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 208000001780 epistaxis Diseases 0.000 description 4
- 208000019622 heart disease Diseases 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 3
- 206010016807 Fluid retention Diseases 0.000 description 3
- 208000034507 Haematemesis Diseases 0.000 description 3
- 206010019468 Hemiplegia Diseases 0.000 description 3
- 206010021118 Hypotonia Diseases 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 208000017561 flaccidity Diseases 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 206010040872 skin infection Diseases 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 2
- 206010010726 Conjunctival oedema Diseases 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 208000024756 faint Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 229940039009 isoproterenol Drugs 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010051244 Dyschezia Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 208000033240 Progressive symmetric erythrokeratodermia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010062104 Renal mass Diseases 0.000 description 1
- 206010042170 Strangury Diseases 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 208000012549 congenital acardia Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000002266 menstruation inducing agent Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于中药领域,具体涉及一种治疗慢性心衰的中药制剂及其制备方法,其特征在于按照重量份数计,由以下中药原料配制而成:三七25~35份、丹参25~35份、红花10~15份、当归25~35份、赤芍10~15份、黄芪25~35份、枸杞1~2份、杜仲10~15份、淫羊藿2~3份、肉桂5~10份、甘松5~10份、五味子20~25份、地龙10~15份、干姜20~25份、巴戟天5~10份、蒲黄25~35份和益母草25~35份。本发明的优点在于所使用的中药符合中华人民共和国药典规定,药物安全可靠。诸药相和具有补益心气、活血化瘀、利水化痰等功效,治疗慢性心衰具有疗效确切、见效快、治愈率高、无副作用等特点。
Description
技术领域
本发明属于中药领域,具体涉及一种治疗慢性心衰的中药制剂及其制备方法。
背景技术
慢性心力衰竭(CHF)是各种心脏疾病的严重或终末阶段的一种临床综合征。导致CHF的常见原因为冠心病、高血压病、糖尿病和各种心肌病等,其中冠心病引起的心衰占首位。
CHF的发病率和死亡率居高不下,与CHF的临床过程有密切的关系。2007中国《慢性心力衰竭诊断和治疗指南》和2005美国的心衰指南均指出CHF是一种进行性的病变,一旦起始,即使没有新的心肌损害,临床亦处于稳定阶段,仍可自身不断发展。因此,美国心衰编写委员会率先发展了心衰分类的新方法,将心衰按其严重程度分为A、B、C、D四个阶段。阶段A为“前心衰阶段”(Pre-Heart Failure),此阶段无心脏的结构或功能异常,也无心衰的症状和(或)体征。多见于心衰的高发危险人群(主要指高血压病、冠心病、糖尿病等),这一阶段的心衰是可以预防的。阶段B属“前临床心衰阶段”(Pre-Clinical HeartFailure),患者从无心衰的症状和(或)体征已发展成结构性心脏病,例如:左室肥厚、无症状瓣膜性心脏病、以往有MI(心肌梗死)史等。这一阶段相当于无症状性心衰,或NYHA心功能Ⅰ级。由于心衰是一种进行性的病变,心肌重构可自身不断地发展,因此,这一阶段病人的积极治疗极其重要,而治疗的关键是阻断或延缓心肌重构。阶段C为临床心衰阶段。患者已有基础的结构性心脏病,以往或目前有心衰的症状和(或)体征;或目前虽无心衰的症状和(或)体征,但以往曾因此治疗过。这一阶段包括NYHAⅡ、Ⅲ级和部分Ⅳ级心功能患者。阶段D为难治性终末期心衰阶段。患者有进行性结构性心脏病,虽经积极的内科治疗,休息时仍有症状,且需要特殊干预。
由此可见,针对心衰阶段B,在心肌梗死或左室肥厚患者的心衰症状出现之前早期采取治疗措施,可降低心衰的发病率和死亡率。
中医药在长期的治病过程中,积累了丰富的经验。中医传统文献中无“心衰”之名,根据其临床特征,涉及中医“喘证”、“水肿”、“心悸”、“怔忡”、“痰饮”、“心痹”等范畴。大多数研究认为,本病属本虚标实、虚实夹杂之证,以心气心阳虚衰为本,血脉瘀滞、水饮内停、痰浊不化为标。
近年来,心衰的发病率和病死率呈现不断上升的趋势,由此产生的医疗费用和社会负担也迅速增加,2005年美国CHF患者达到550万,直接或间接用于治疗CHF的费用高达279亿美元。我国对35~74岁城乡居民共15518人随机抽样调查的结果:心衰患病率为0.9%,按计算约有400万心衰患者,其中男性为0.7%,女性为1.0%。Framingham研究显示,CHF5年存活率,男性为25%,女性为38%,重症患者一般存活不到1年。据我国部分地区42家医院,在1980、1990、2000年3个全年段,对心衰住院病例共10714例所作的回顾性调查,病因中冠心病由1980年的36.8%上升至2000年的45.6%,居各种病因之首;与我国相邻的日本的一项研究,对8个城市的15所医院共3169名心衰患者进行了调查,发现冠
心病在心衰病因中也占首要地位(33.5%);Framingham研究发现,当年龄到40岁时,人群发生心衰的危险性明显增高(男性:21%,女性:20%),而且这种危险性与心肌缺血及血压水平密切相关。
治疗CHF的传统药物主要包括利尿剂、ACEI(血管紧张素转换酶抑制剂)类、血管扩张剂、强心剂、心肌营养剂、钙通道阻滞剂等,但并未从根本上提高患者的生活质量,也未能有效降低CHF的死亡率,临床应用中也存在诸多问题。随着对CHF发生和发展基本病理机制——心肌重构的认识,传统的强心、利尿、扩血管的常规治疗理念正在逐步淡化,从短期的药理学措施改善症状,逐渐转变为长期的、修复性的策略及对CHF发病机制的干预。
发明内容
根据以上现有技术的不足,本发明提供一种治疗慢性心衰的中药制剂及其制备方法,其疗效显著、安全可靠、无毒副作用,具有广阔的临床应用前景。
本发明所述的一种治疗慢性心衰的中药制剂,按照重量份数计,由以下中药原料配制而成:三七25~35份、丹参25~35份、红花10~15份、当归25~35份、赤芍10~15份、黄芪25~35份、枸杞1~2份、杜仲10~15份、淫羊藿2~3份、肉桂5~10份、甘松5~10份、五味子20~25份、地龙10~15份、干姜20~25份、巴戟天5~10份、蒲黄25~35份和益母草25~35份。
其中,优选方案如下:
按照重量份数计,由以下中药原料配制而成:三七25份、丹参25份、红花10份、当归25份、赤芍10份、黄芪25份、枸杞1份、杜仲10份、淫羊藿2份、肉桂5份、甘松5份、五味子20份、地龙10份、干姜20份、巴戟天5份、蒲黄25份和益母草25份。
也可以按照重量份数计,由以下中药原料配制而成:三七35份、丹参35份、红花15份、当归35份、赤芍15份、黄芪35份、枸杞2份、杜仲15份、淫羊藿3份、肉桂10份、甘松10份、五味子25份、地龙15份、干姜25份、巴戟天10份、蒲黄35份和益母草35份。
本发明所述的治疗慢性心衰的中药制剂的制备方法,按照以下方法制备:按照配方称取中药原料并加入到容器中,加水漫过药面浸泡10~20分钟,再加水没过药面3~5厘米,用武火煎煮至沸腾再改用文火煎煮20~30分钟,取滤液;然后再加水没过药面3~5厘米,用武火煎煮至沸腾再改用文火煎煮15~20分钟,然后去渣取滤液,两次滤液合并即可。
使用时,每次200~300ml,早晚各一次。
药理分析:
三七:甘微苦,温,无毒。入肝、胃,兼入心、大肠。止血,散瘀,消肿,定痛。治吐血,咳血,衄血,便血,血痢,崩漏,症瘕,产后血晕,恶露不下,跌扑瘀血,外伤出血,痈肿疼痛。
丹参:味苦,性微寒。根入药,含丹参酮,为强壮性通经剂,有祛瘀、生新、活血、调经等效用,为妇科要药,主治子宫出血,月经不调,血瘀,腹痛,经痛,经闭,庙痛。对治疗冠心病有良好效果。此外亦治神经性衰弱失眠,关节痛,贫血,乳腺炎,淋巴腺炎,关节炎,疮疖痛肿,丹毒,急慢性肝炎,肾孟肾炎,跌打损伤,晚期血吸虫病肝脾肿大,癫癎。
红花:辛,温,无毒。入心、肝经。活血通经,去瘀止痛。治经闭,症瘕,难产,死胎,产后恶露不行、瘀血作痛,痈肿,跌扑损伤。
当归:味甘,温。归肝、心、脾经。补血;活血;调经止痛;润燥滑肠。主治血虚诸证:月经不调;经闭;痛经;症瘕结聚;崩漏;虚寒腹痛;痿痹;肌肤麻木;肠燥便难;赤痢后重;痈疽疮疡;跌扑损伤。
赤芍:苦,微寒。归肝经。清热凉血;活血祛瘀。主温毒发斑;吐血衄血;肠风下血;目赤肿痛;痈肿疮疡;闭经;痛经;崩带淋浊;瘀滞胁痛;疝瘕积聚;跌扑损伤。用于温毒发斑,吐血衄血,目赤肿痛,肝郁胁痛,经闭痛经,症瘕腹痛,跌扑损伤,痈肿疮疡。
黄芪:补气固表,托毒排脓,利尿,生肌。用于气虚乏力、久泻脱肛、自汗、水肿、子官脱垂、慢性肾炎蛋白尿、糖尿病、疮口久不愈合。
枸杞:甘,平。归肝、肾经。滋补肝肾,益精明目。用于虚劳精亏,腰膝酸痛,眩晕耳鸣,内热消渴,血虚萎黄,目昏不明。
杜仲:甘,温,无毒。归肝、肾经。杜仲具有补肝肾,治腰脊酸疼,足膝痿弱,小便余沥,阴下湿痒,高血压、安胎的功效。杜仲对免疫系统、内分泌系统、中枢神经系统、循环系统和泌尿系统都有不同程度的调节作用,杜仲能兴奋垂体-肾上腺皮质系统,增强肾上腺皮质功能。
淫羊藿:辛、甘,温。归肝、肾经。补肾壮阳,祛风除湿。治阳痿不举,偏风不遂,小便淋沥,筋骨挛急,咳嗽,病后青盲,虚火牙痛,半身不遂,腰膝无力,风湿痹痛,四肢不仁。
肉桂:辛、甘,大热。辛、甘,大热。补火助阳,引火归源,散寒止痛,活血通经。用于阳痿,宫冷,腰膝冷痛,肾虚作喘,阳虚眩晕,目赤咽痛,心腹冷痛,虚寒吐泻,寒疝,奔豚,经闭,痛经。
甘松:味辛;甘;性温。归脾;胃经。理气止痛;醒脾健胃。主治脘腹胀痛;不思饮食;牙痛;脚气。
五味子:酸、甘,温。归肺,心、肾经。收敛固涩,益气生津,补肾宁心。用于久嗽虚喘,梦遗滑精,遗尿尿频,久泻不止,自汗,盗汗,津伤口渴,短气脉虚,内热消渴,心悸失眠。
地龙:咸,寒。归肝、脾、膀胱经。清热定惊,通络,平喘,利尿。用于高热神昏,惊痫抽搐,关节痹痛,肢体麻木,半身不遂,肺热喘咳,尿少水肿,高血压。
干姜:味辛,性热。归脾、胃、心、肺经。温中散寒,回阳通脉,燥湿消痰,温肺化饮。主治脘腹冷痛、呕吐、泄泻、亡阳厥逆、寒饮喘咳、寒湿痹痛。
巴戟天:甘,辛,微温。归肾、肝经。补肾阳,强筋骨,祛风湿。用于阳痿遗精,宫冷不孕,月经不调,少腹冷痛,风湿痹痛,筋骨痿软。
蒲黄:甘,平。归肝、心包经。止血,化瘀,通淋。用于吐血,衄血,咯血,崩漏,外伤出血,经闭痛经,脘腹刺痛,跌扑肿痛,血淋涩痛。
益母草:味辛苦、凉,活血、祛淤、调经、消水,治疗妇女月经不调,胎漏难产,胞衣不下,产后血晕,瘀血腹痛,崩中漏下,尿血、泻血,痈肿疮疡。益母草可促进由异丙肾上腺素造成的局部血流微循环障碍的很快恢复。异丙肾上腺素50毫克/千克,皮下注射制造大鼠心肌缺血坏死;分别于24小时后选择T波压低和T波高的心电图,4天后选择双相T波心电图,用益母草制剂治疗,结果经治疗1小时内,大部分动物的心电图均恢复正常,显示对心肌早期缺血(24小时)甚至病变,接近缺血坏死。
本发明的优点在于所使用的中药符合中华人民共和国药典规定,药物安全可靠。诸药相和具有补益心气、活血化瘀、利水化痰等功效,治疗慢性心衰具有疗效确切、见效快、治愈率高、无副作用等特点。
疗效判断:
1、病例选择:
作为治疗慢性心衰的药物,选择慢性心衰患者100例进行临床观察,其中男52例,女性48例,年龄45-85岁,平均年龄55岁,病程1-10年,平均1.2年。
2、治疗用药:
治疗组患者服用本发明药物,每次200~300ml,早晚各一次,7天为一个疗程,根据病情连续服用3-4个疗程,病情严重者遵医嘱酌增用量。
3、疗效判断:
根据美国纽约心脏病学会心衰分级标准(NYHA分级),无心衰者BNP<80ng/L、心功能Ⅰ级者BNP 95~221ng/L、心功能Ⅱ级患者BNP 221~459ng/L、心功能Ⅲ级患者BNP 459~1006ng/L、心功能Ⅳ级患者BNP≥1006ng/L。目前,在国际上把心衰患者BNP的阳性阈值定为100ng/L,当BNP测值在正常值以下时,可以认为能够排除心衰。
显效:临床症状基本消失,试验室检查各相关指标接近正常水平,BNP<100ng/L。
有效:临床症状减轻,试验室检查各相关指标有所改善,NYHA分级向好转方向提升,体征有改善。
无效:临床症状无明显好转或加重。
4、治疗结果:
显效30例,有效62例,无效8例,总有效率为92%。
以下列举一个典型病例:
王某,女,72岁,山东青岛人,慢性心衰20余年,心率85次/分,血压145/85mmHg,心功能NYHAⅢ级,呼吸困难,左心射血分数37%,24h尿量约为620ml,全身水肿,体重68.6kg。治疗前24h呋塞米用量1600mg和安体舒通用量为180mg,血尿素氮27.7mmol/l,血肌酐468.7mmol/l,血电解质常出现紊乱。服用本发明制剂第一个疗程时,心率75次/分,心功能改善为Ⅱ级,左心射血分数48%,体重为70kg,日尿量约为1440ml,血压135/70mmHg,呼吸困难和水肿明显改善。随访至第二疗程,上述指标进一步改善。
具体实施方式
以下结合实施例对本发明做进一步说明。
实施例1:
一种治疗慢性心衰的中药制剂,按照重量份数计,由以下中药原料配制而成:三七25份、丹参25份、红花10份、当归25份、赤芍10份、黄芪25份、枸杞1份、杜仲10份、淫羊藿2份、肉桂5份、甘松5份、五味子20份、地龙10份、干姜20份、巴戟天5份、蒲黄25份和益母草25份。
实施例2:
:一种治疗慢性心衰的中药制剂,按照重量份数计,由以下中药原料配制而成:三七35份、丹参35份、红花15份、当归35份、赤芍15份、黄芪35份、枸杞2份、杜仲15份、淫羊藿3份、肉桂10份、甘松10份、五味子25份、地龙15份、干姜25份、巴戟天10份、蒲黄35份和益母草35份。
实施例3:
实施例1所述配方按照以下方法制备治疗慢性心衰的中药制剂:按照配方称取中药原料并加入到容器中,加水漫过药面浸泡10分钟,再加水没过药面3厘米,用武火煎煮至沸腾再改用文火煎煮20分钟,取滤液;然后再加水没过药面3厘米,用武火煎煮至沸腾再改用文火煎煮15分钟,然后去渣取滤液,两次滤液合并即可。
实施例4:
实施例2所述配方按照以下方法制备治疗慢性心衰的中药制剂:按照配方称取中药原料并加入到容器中,加水漫过药面浸泡20分钟,再加水没过药面5厘米,用武火煎煮至沸腾再改用文火煎煮30分钟,取滤液;然后再加水没过药面5厘米,用武火煎煮至沸腾再改用文火煎煮20分钟,然后去渣取滤液,两次滤液合并即可。
Claims (4)
1.一种治疗慢性心衰的中药制剂,其特征在于按照重量份数计,由以下中药原料配制而成:三七25~35份、丹参25~35份、红花10~15份、当归25~35份、赤芍10~15份、黄芪25~35份、枸杞1~2份、杜仲10~15份、淫羊藿2~3份、肉桂5~10份、甘松5~10份、五味子20~25份、地龙10~15份、干姜20~25份、巴戟天5~10份、蒲黄25~35份和益母草25~35份。
2.根据权利要求1所述的一种治疗慢性心衰的中药制剂,其特征在于按照重量份数计,由以下中药原料配制而成:三七25份、丹参25份、红花10份、当归25份、赤芍10份、黄芪25份、枸杞1份、杜仲10份、淫羊藿2份、肉桂5份、甘松5份、五味子20份、地龙10份、干姜20份、巴戟天5份、蒲黄25份和益母草25份。
3.根据权利要求1所述的一种治疗慢性心衰的中药制剂,其特征在于按照重量份数计,由以下中药原料配制而成:三七35份、丹参35份、红花15份、当归35份、赤芍15份、黄芪35份、枸杞2份、杜仲15份、淫羊藿3份、肉桂10份、甘松10份、五味子25份、地龙15份、干姜25份、巴戟天10份、蒲黄35份和益母草35份。
4.一种权利要求1所述的治疗慢性心衰的中药制剂的制备方法,其特征在于按照以下方法制备:按照配方称取中药原料并加入到容器中,加水漫过药面浸泡10~20分钟,再加水没过药面3~5厘米,用武火煎煮至沸腾再改用文火煎煮20~30分钟,取滤液;然后再加水没过药面3~5厘米,用武火煎煮至沸腾再改用文火煎煮15~20分钟,然后去渣取滤液,两次滤液合并即可。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410758521.3A CN104524491A (zh) | 2014-12-10 | 2014-12-10 | 一种治疗慢性心衰的中药制剂及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410758521.3A CN104524491A (zh) | 2014-12-10 | 2014-12-10 | 一种治疗慢性心衰的中药制剂及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104524491A true CN104524491A (zh) | 2015-04-22 |
Family
ID=52840247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410758521.3A Pending CN104524491A (zh) | 2014-12-10 | 2014-12-10 | 一种治疗慢性心衰的中药制剂及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104524491A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105435131A (zh) * | 2016-01-14 | 2016-03-30 | 青岛友诚高新技术有限公司 | 一种治疗慢性心衰的中药组合物及其制备方法 |
-
2014
- 2014-12-10 CN CN201410758521.3A patent/CN104524491A/zh active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105435131A (zh) * | 2016-01-14 | 2016-03-30 | 青岛友诚高新技术有限公司 | 一种治疗慢性心衰的中药组合物及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101926961B (zh) | 一种内服治疗盆腔炎的中药组合物 | |
| CN103705809B (zh) | 一种治疗痛风的中药 | |
| CN104667047A (zh) | 一种治疗糖尿病足的中药液 | |
| CN104758852A (zh) | 一种治疗高血压的中药组合物 | |
| CN104800634A (zh) | 一种治疗高血压的药物及其制备方法 | |
| CN106267105A (zh) | 一种治疗颈椎病及骨关节疾病的内服药物及其制备方法 | |
| CN105213906A (zh) | 一种用于治疗痛风的中药组合物及其制备方法 | |
| CN103585453B (zh) | 一种治疗高血压的中药 | |
| CN102526581B (zh) | 一种用于治疗高血压疾病的中药组合物 | |
| CN105168881A (zh) | 一种治疗慢性肾衰竭ⅰ,ⅱ期的中药组合物 | |
| CN105726931A (zh) | 一种治疗慢性心衰的中药制剂及其制备方法 | |
| CN104383268A (zh) | 一种治疗高血压的中药组合物 | |
| CN101204494B (zh) | 一种治疗慢性肠炎的药物 | |
| CN104524491A (zh) | 一种治疗慢性心衰的中药制剂及其制备方法 | |
| CN106267098A (zh) | 一种可有效治疗痛风的中药组合物及其制备方法 | |
| CN105079549A (zh) | 一种治疗狼疮性肾炎的中药 | |
| CN106110237A (zh) | 一种治疗冠心病心绞痛的汤剂药物及其制备方法 | |
| CN105726854A (zh) | 治疗慢性心衰的中药制剂及其制备方法 | |
| CN104013762A (zh) | 一种治疗月经量过多的中药组合物 | |
| CN104547398A (zh) | 治疗慢性心衰的中药制剂及其制备方法 | |
| CN102552629B (zh) | 一种治疗风寒湿痹症的中药 | |
| CN103285360B (zh) | 一种治疗血栓闭塞性脉管炎的中药制剂及其制备方法 | |
| CN107050407A (zh) | 一种可有效治疗月经不调的汤剂药物及其制备方法 | |
| CN106362097A (zh) | 一种治疗肾阳虚的中药组合物及制备方法 | |
| CN104027528A (zh) | 一种治疗肾炎的中药丸 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150422 |